01—Abstract
Summary
Summary of the 8-K/A filed July 7, 2025. Cited figures are marked; the original filing is the authoritative source.
CoreWeave, Inc. (CRWV) has filed an 8-K report detailing a material definitive agreement: an Agreement and Plan of Merger.
This agreement outlines the terms under which CoreWeave (referred to as 'Parent' in the filing) will acquire Core Scientific, Inc. (the 'Company') through a merger. The transaction is structured as a stock-for-stock exchange where each share of Core Scientific common stock will be converted into 0.1235 shares of CoreWeave's Class A common stock. This acquisition represents a significant strategic move for CoreWeave, likely aimed at expanding its market position and capabilities within the high-performance computing and AI infrastructure sector.
The merger is subject to customary closing conditions, including Core Scientific stockholder approval, the effectiveness of a registration statement for CoreWeave's shares, and regulatory approvals such as the Hart-Scott-Rodino Act. The agreement also details the treatment of Core Scientific's outstanding equity awards, stock options, warrants, and convertible notes, which will be converted into equivalent instruments or cash consideration based on the exchange ratio and specific terms. Investors should note the potential termination fees and the long-stop date of April 7, 2026, for the completion of the merger.
02—Key points
Key Highlights
- CoreWeave (Parent) to acquire Core Scientific, Inc. (Company) via a merger.
- Core Scientific shareholders will receive 0.1235 shares of CoreWeave Class A common stock for each share of Core Scientific common stock.
- Outstanding equity awards, stock options, warrants, and convertible notes of Core Scientific will be converted into CoreWeave instruments or cash.
- The transaction is subject to customary closing conditions, including stockholder approval and regulatory reviews.
- A termination fee of $270.0 million is payable by Core Scientific to CoreWeave under certain circumstances.
- The merger is expected to close by April 7, 2026, unless extended.
- This filing initiates the formal process for the acquisition, with further details to be provided in SEC filings like a Form S-4.
03—Questions
Frequently Asked Questions
What is the primary purpose of this 8-K filing?
This 8-K filing announces that CoreWeave, Inc. ('Parent') has entered into a definitive agreement to acquire Core Scientific, Inc. ('Company') through a merger. It details the key terms of the merger agreement, including the exchange ratio and how existing Core Scientific equity and debt instruments will be treated.
How will Core Scientific shareholders be compensated in this acquisition?
Core Scientific shareholders will receive 0.1235 shares of CoreWeave's Class A common stock for each share of Core Scientific common stock they own. This is a stock-for-stock transaction.
What are the key conditions that must be met for this merger to be completed?
The merger is contingent upon several conditions, including: adoption of the merger agreement by Core Scientific stockholders, effectiveness of a registration statement for the CoreWeave shares to be issued, expiration of any waiting period under the Hart-Scott-Rodino Antitrust Improvements Act, absence of any governmental injunctions, and approval for listing of CoreWeave's Class A common stock on the Nasdaq Global Select Market.
Are there any penalties for terminating the merger agreement?
Yes, the merger agreement includes termination rights for both parties. If Core Scientific terminates the agreement under specific circumstances, such as entering into a superior proposal, or if the company's board changes its recommendation, Core Scientific may be required to pay CoreWeave a termination fee of $270.0 million.
04—Continue